Video Experimental Relacionado
Updated: Apr 23, 2026
04:41
Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research
Published on: October 13, 2023
2.1K
Epilepsia: nuevos avances en el campo
Solomon L Moshé1, Emilio Perucca2, Philippe Ryvlin3
1Saul R Korey Department of Neurology, Dominick P Purpura Department of Neuroscience and Department of Pediatrics, Laboratory of Developmental Epilepsy, Montefiore/Einstein Epilepsy Management Center, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, NY, USA.
Lancet (London, England)
|September 28, 2014
Resumen
La epilepsia afecta a millones de personas en todo el mundo, causando discapacidad y altos costos. A pesar de los avances en la comprensión y el tratamiento, muchos pacientes siguen siendo resistentes a las terapias, lo que pone de relieve las brechas críticas en la atención y la investigación.
Área de la Ciencia:
- Neurología Neurología.
- La medicina clínica es la medicina clínica.
- Salud Pública La salud pública.
Sus antecedentes:
- La epilepsia afecta a 65 millones de personas en todo el mundo, lo que plantea desafíos significativos en cuanto a discapacidad, mortalidad, comorbilidades, estigma y carga económica.
- En las últimas décadas se ha avanzado en la comprensión de la fisiopatología y los factores pronósticos de la epilepsia.
- Esto ha llevado a definiciones actualizadas, criterios de diagnóstico y sistemas de clasificación para la epilepsia.
Objetivo del estudio:
- Revisar el panorama actual del manejo de la epilepsia e identificar los desafíos persistentes.
- Para resaltar los avances en la comprensión y el tratamiento al tiempo que reconoce las necesidades no satisfechas.
Principales métodos:
- Revisión de la literatura de los avances recientes en la investigación de la epilepsia y la práctica clínica.
- Análisis de los resultados del tratamiento para los medicamentos antiepilépticos y las intervenciones quirúrgicas.
- Evaluación de las brechas existentes en el conocimiento, el diagnóstico, el tratamiento y el apoyo al paciente.
Principales resultados:
- A pesar de un aumento sustancial en los medicamentos antiepilépticos en los últimos 20 años, aproximadamente un tercio de los pacientes presentan resistencia a los medicamentos.
- La cirugía de epilepsia ofrece una significativa libertad de convulsiones para más de la mitad de los pacientes, pero está subutilizada.
- Persisten brechas en el conocimiento, el diagnóstico, el tratamiento, la promoción, la educación, la legislación y la investigación.
Conclusiones:
- Persisten desafíos significativos en el manejo de la epilepsia, particularmente los casos resistentes a los medicamentos.
- Las modalidades actuales de tratamiento, incluida la cirugía, no están llegando a todos los pacientes elegibles.
- Se requieren acciones urgentes y concertadas para abordar los desafíos multifacéticos en la atención e investigación de la epilepsia.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:24Epilepsy and Seizures: Overview
1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
01:22Epilepsy ll: Types
24
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
24
01:20Seizures l: Introduction
27
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
27
01:13Seizures: Classification
2.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
01:19Seizures ll: Types
23
Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
23
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K